Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
35 hedge funds and large institutions have $14.7M invested in Cellular Biomedicine Group, Inc. in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
375% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 4
17% more funds holding
Funds holding: 30 → 35 (+5)
22% less capital invested
Capital invested by funds: $18.9M → $14.7M (-$4.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$963K |
| 2 |
Goldman Sachs
New York
|
+$300K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$274K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$231K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$161K |
| 2 |
Citigroup
New York
|
-$110K |
| 3 |
State Street
Boston,
Massachusetts
|
-$35.8K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$15.2K |
| 5 |
Morgan Stanley
New York
|
-$739 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $23K | +$7.92K | +493 | +34% |
|
27
BlackRock
New York
| $19K | +$15.4K | +959 | +159% |
|
|
28
Citigroup
New York
| $15K | -$110K | -6,866 | -85% |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| $10K | +$13.5K | +838 | +2,793% |
|
30
BNP Paribas Financial Markets
Paris,
France
| $8.07K | +$9.53K | +593 | +741% |
|
31
Creative Planning
Overland Park,
Kansas
| $4K | – | – | – |
|
32
Bank of America
Charlotte,
North Carolina
| $4K | +$5.28K | +329 | New |
|
|
33
Morgan Stanley
New York
| $1K | -$739 | -46 | -48% |
|
|
MFS
34
MSI Financial Services
Springfield,
Massachusetts
| $1K | – | – | – |
|
|
MLICM
35
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$161K | -8,651 | Closed |
|
|
JCM
36
Jacobi Capital Management
Pittston,
Pennsylvania
| – | +$16 | +1 | New |
|
CBMG Hedge Fund Activity: Q2 2016 in Review
35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q2 2016, worth a combined $14.7M — down 22% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CBMG positions and 1 closed out — a net gain of 5 holders — while 19 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $963K. The largest seller was Metropolitan Life Insurance Company (MetLife), exiting entirely with an estimated $161K sold.
- 35 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q2 2016, up from 30 in Q1 2016.
- Funds reported $14.7M of Cellular Biomedicine Group, Inc. stock for Q2 2016, down 22% quarter-over-quarter.
- 6 funds opened new Cellular Biomedicine Group, Inc. positions in Q2 2016 and 1 closed out, a net change of +5 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $963K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q2 2016 was Metropolitan Life Insurance Company (MetLife), an estimated $161K sold.
Based on aggregated 13F filings for Q2 2016.